bluebird bio, Inc.
NASDAQ:BLUE
0.61 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | bluebird bio, Inc. |
Symbool | BLUE |
Munteenheid | USD |
Prijs | 0.606 |
Beurswaarde | 116,763,104 |
Dividendpercentage | 0% |
52-weken bereik | 0.52 - 5.53 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew Obenshain |
Website | https://www.bluebirdbio.com |
An error occurred while fetching data.
Over bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)